Regulatory10 Aug 2026, 07:40 pm
Ind-Swift Labs Reports NIL Deviation in Preferential Issue Funds
AI Summary
Ind-Swift Laboratories Ltd has filed a Statement of NIL Deviation for the quarter ended June 30, 2026, confirming no variation in the use of funds raised through a Preferential Issue of Convertible Warrants. The company raised ₹255.61 Crores out of a total issue size of ₹314.60 Crores. A note clarifies that ₹58.99 Crores became non-receivable as an allottee failed to exercise its conversion rights, revising the monitored amount to ₹255.61 Crores. Funds were utilized for business expansion, investments in subsidiaries, working capital, and general corporate purposes, with no deviation from the original allocation.
Key Highlights
- No deviation reported in the utilization of funds from preferential issue.
- ₹58.99 Cr became non-receivable due to warrant non-conversion.
- Revised monitored amount stands at ₹255.61 Crores.
- Funds utilized for expansion, subsidiaries, working capital, and general purposes.
- Statement reviewed by the Audit Committee.
Price Impact
More from INDSWFTLAB